An observational study in Chronic Pain, Post Intensive Care Unit Syndrome and Quality of Life, sponsored by Zealand University Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by Zealand University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Chronic Pain with a site in Denmark — 14 open to participants now, 16 under way, none of them phase 3. Chronic Pain · Denmark.
Among the 90 studies in Chronic Pain with a site in Denmark, this one is the 9th largest by planned enrollment of the 33 observational ones that give a count, is one of 3 that started in 2025, is one of 33 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 83rd registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →14 of the 90 studies in Chronic Pain with a site in Denmark are open now. Recruiting first, the newest first:
Vejle Hospital · Sites in Denmark
Ages 18–70
Vejle Hospital · Sites in Denmark
Ages 18–70
Aalborg University · Sites in Denmark
Ages 18–80
University of Aarhus · Sites in Denmark
Ages 18+
Aalborg University · Sites in Denmark
Ages 18–80
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9 · Phase 4 6
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 120 across 755 observational studies indexed under Chronic Pain.
Median enrollment 71 across the 57 interventional studies, 134 across the 33 observational. Of the 65 that completed or were terminated, 6 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 90 have an industry lead sponsor. The 10 most frequent:
Zealand University Hospital is the lead sponsor of 237 studies on the registry; 50 are open to participants now.
Zealand University Hospital has 3 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
3 of the studies in Chronic Pain with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07180407Zealand University HospitalThe Post-ICU Pain Study | 2027-01 |
| NCT07266103Aalborg UniversityMechanistic Study of Personalized rTMS in Chronic Pain | 2027-06-30 |
| NCT07293130Claus KjærgaardProtocol for a Randomized Controlled Trial Comparing the Effectiveness of Mechanical Diagnosis and Therapy Versus Generalized Exercise for Reducing Pain in Surgeons With Chronic Spinal Pain | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies in Chronic Pain with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BACKGROUND: ICU survivors may experience serious psychological, physical and cognitive impairments following ICU admission, collectively termed Post Intensive Care Syndrome (PICS). Persistent pain is an underrecognized component of PICS. Previous research has shown that persistent pain is a profound clinical challenge in ICU survivors, however, research demonstrates conflicting results. Furthermore, no studies have examined the prevalence of persistent pain in ICU survivors in a contemporary Danish ICU setting.
OBJECTIVES: We aim to examine the clinical trajectory, risk factors, and pathophysiology of persistent pain in ICU survivors in Denmark.
DESIGN AND SAMPLE SIZE: The study is designed as a multicenter, prospective, inception cohort study with clinical follow-up. Based on the pre-study sample size calculation, 800 patients will be included. Patients will be contacted by telephone 90 days and 180 days after ICU discharge, and a series of questionnaires regarding pain, sleep quality, affective state and quality of life will be completed. A subgroup of patients will undergo a detailed clinical examination including quantitative sensory testing between 180-365 days after ICU discharge.
POPULATION: Patients will be recruited from 4 Danish ICU departments. Inclusion criteria include adult patients (18 years of age), acute admission to the ICU, and an ICU admission of a minimum of 48 hours.
OUTCOMES: The primary outcome is the prevalence of pain assessed by the Brief Pain Inventory (BPI) at 90 and 180 days after ICU discharge. Secondary outcomes include additional detailed descriptions of pain and daily activity, sleep quality, affective state, quality of life, treatment- and patient-related risk factors, and biomarkers associated with development of persistent pain.
Substudies:
- QST substudy: 80 participants (40 with pain and 40 without pain) recruited from the main cohort will undergo Quantative Somatosensory Testing (QST). The objectives are first, to delineate somatosensory profiles of ICU survivors with and without pain, and second, to examine the presence of neuropathic pain in ICU survivors.
Patients admitted to the ICU
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prevalence of pain
Patients are defined as having pain if they answer "yes" to question number 1 in the Brief Pain Inventory - Short Form
Time frame: 180 day follow-up
Brief Pain Inventory - Short Form (BPI-SF)
Additional components of the Brief Pain Invenstory Short Form
Time frame: At follow-up at 90 and 180 days
Incidence of new-onset persistent pain after ICU discharge
Definition of new-onset persistent pain: Individuals presenting with pain according to Brief Pain Inventory Short Form at 90 AND 180 days follow-up AND not suffering from persistent pain/using pain medication regularly before ICU admission, as reported by the individual.
Time frame: at 90 and 180 days follow-up
Quality of life measured by EuroQol-5-domain 5-level (EQ-5D-5L)
The EQ-5D-5L comprises 5 components (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression) which can be rated at 5 levels. Furthermore, a Visual Analog Scale (VAS) documents self-rated health
Time frame: at 90 and 180 days
The Single Item Sleep Quality Scale (SQS)
The respondent is asked to rate the overall quality of sleep over a 7-day recall period on a VAS. Respondents are instructed to consider the following components before answering the questionnaire: hours of sleep, night wakings, how easily they fall asleep, how often they wake earlier then needed, and how refreshed they feel when waking. Sleep quality is scored as follows: 0 = terrible, 1-3 = poor, 4-6 = fair, 7-9 = good, and 10 = excellent
Time frame: at 90 and 180 days
Hospital Anxiety and Depression Scale (HADS)
It comprises seven questions regarding anxiety and seven questions regarding depressive symptoms. Anxiety and depression are scored separately with recommended cut-off values of 8-10 for possible presence of a mood disorder and \>11 for probable presence of a mood disorder
Time frame: at 90 and 180 days
Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS)
Only patients answering "yes" to the Brief Pain Inventory Short Form, question number 1, will be asked to fill out the S-LANSS. The tool was created as a clinical tool to identify pain primarily of neuropathic origin, allowing for the differentiation between neuropathic pain and nociceptive pain. It contains 7 items assessing pain quality, sensory changes and specific symptoms commonly associated with neuropathic pain. A score above 12 suggests neuropathic pain
Time frame: 90 and 180 days
30-day mortality
Time frame: 30 days
90-day mortality
Time frame: 90 days
180 days mortality
Time frame: 180 days
The Short Physical Performance Battery (SPPB)
QST SUBSTUDY: This test includes a series of tasks designed to examine physical performance. The SPPB requires limited space and takes about 10 minutes to complete. It contains 3 domains (3 m gait speed, 5 times chair stands, and 3 progressive standing balance tasks). Each component is scored separately, and a total score is calculated. The maximum score is 12 indicating little to no mobility impairment
Time frame: between 180 days followup and 360 days.
PainDETECT (PD-Q)
QST SUBSTUDY: The questionnaire assesses pain intensity (three questions), pain course patterns, the location of pain and presence of radiating pain (via a body chart), and sensory descriptors of pain (seven questions). Scores of 0-12 indicate neuropathic pain component is unlikely, scores of 12-18 indicates results are ambiguous, however a neuropathic component can pe present, and lastly scores of 19-38 indicates neuropathic pain component is likely
Time frame: between 180 days followup and 360 days
QST outcomes
QST SUBSTUDY: \- simple reaction time (seconds)
Time frame: between 180 days followup and 360 days
QST outcomes
QST SUBSTUDY: \- Thermal thresholds: Thresholds are determined by increasing the thermode temperature from baseline 32°C (ramp rate + 1.0 °C/s) until the subject activates the 'stop' button. WDT is defined as the point at which the patient first perceives a sensation of warmth. HPT is defined as the point at which the thermal sensation first turns into pain. The cut-off temperature is 50°C, avoiding the risk of thermal skin injuries
Time frame: between 180 days followup and 360 days
QST outcomes
QST SUBSTUDY: \- Pinprick thresholds and temporal summation (mN)
Time frame: between 180 days followup and 360 days
QST outcomes
QST SUBSTUDY: \- Offset analgesia (numeric rating scale; 0-100).
Time frame: between 180 days followup and 360 days
QST outcomes
QST SUBSTUDY: \- Conditioned pain modulation (seconds): includes the cold pressor test (CPT; conditioning stimulus) and pressure algometry (test stimulus).
Time frame: between 180 days followup and 360 days
Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.
Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 16 months is below that.
Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.